Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Autologous hematopoietic stem cell transplantation in multiple sclerosis: A 20-year single center's experience in Mexico.
Multiple Sclerosis
P14 - Poster Session 14 (11:45 AM-12:45 PM)
3-015

Autologous Hematopoietic Stem Cell treatment (AHSCT) is an immune reconstitution treatment option for Multiple Sclerosis (MS) that has grown in clinical evidence over the last decades; detailed efficacy and safety data is still lacking, especially outcomes data from low-income countries. 

To describe the clinical characteristics and clinical outcomes of AHSCT in Mexican patients.

Retrospective single-center observational study of all MS patients that underwent AHSCT in a single reference center in Mexico City from January 2000 to January 2020. 

We identified 24 patients, of which 22 had at least one year of follow-up after AHSCT and underwent analysis for clinical outcome. The median follow-up time was 85 months (range: 12-267); with a median age of 44.0 years (IR 38-52); 62.8% (n=15) were men and 31.8% (n=7) women; 50% were secondary progressive forms of MS (SPMS), and 27.3% were relapsing-remitting MS (RRMS); 59% (n=13) met the criteria for highly active MS (HAMS). 

The composite score of no evidence of disease activity 3 or NEDA3 (no relapses, no new MRI lesions, and no EDSS progression) was achieved in all the patients at a 24-month follow-up and in 72.1% (n=16) of the patients at the time of the last follow up visit. Relapse-free survival at the last follow-up visit was achieved at 77.3%; MRI event-free survival at 90.9%; Expanded disability status scale score progression-free survival in 95.4%. Only one patient required the re-initiation of disease-modifying therapy.  

There was no treatment-related mortality. One patient was diagnosed with premature ovarian failure.

AHSCT in Mexican MS patients is an effective and relatively safe treatment option with no mortality and can be performed with a reasonable degree of safety at experienced centers.

Authors/Disclosures
Mario Enrique Rodriguez Estrada, MD (Mexican Institute of Social Security)
PRESENTER
Dr. Rodriguez Estrada has nothing to disclose.
Luis Enrique Molina Carrion, MD (Hospital Angeles Clinica Londres) Dr. Molina Carrion has nothing to disclose.